|
|
|
|
|
Teisinis statusas
Patento galiojimo terminas pasibaigęs
| (51) | INT.CL. | G01N 33/53 | (2006.01) |
| A61K 38/18 | (2006.01) | ||
| A61K 38/19 | (2006.01) | ||
| A61P 3/06 | (2006.01) | ||
| A61P 3/10 | (2006.01) |
| (11) | Patento numeris | 2219031 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10165256.8 |
| Europos patento paraiškos padavimo data | 2002-10-22 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-08-18 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2013-04-24 |
| (46) | Apibrėžties vertimo paskelbimo data | 2013-10-25 |
| (30) | Numeris | Data | Šalis |
| 336394 P | 2001-10-22 | US |
| (72) |
Depaoli, Alex M, US
Oral, Elif Arioglu, US
Taylor, Simeon I, US
Garg, A., US
|
| (73) |
THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,
201 West 7th Street, Austin, Texas 78701,
US
Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US The Government of the United States of America, represented by The Secretary, Department of Health and Human Services, National Institutes of Health Office of Technology Transfer Suite 325, 6011 Executive Boulevard, Rockville, MD 20852, US |
| (74) |
Marius JAKULIS - JASON,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Leptino naudojimas žmonių lipoatrofijos gydymui ir polinkio tokiam gydymui nustatymo būdas |
| Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| Mokėjimo data | Galiojimo metai | Suma | |
| 2021-09-24 | 347.00 EUR |